Endeavor BioMedicines
Latest round
- Series C
Last raised
- Apr 2024
Total raised
- $284M
Investors
- 17
About Endeavor BioMedicines
a. Endeavor BioMedicines operates as a developer of therapies and medicines for patients with life-threatening diseases such as fibrotic lung diseases and cancer. In April 2024, Endeavor BioMedicines, Inc. The company’s pipeline includes ENV-101 (IPF), ENV-101 (PPF), and ENV-501 (oncology). Endeavor BioMedicines is developing taladegib, a small-molecule inhibitor of the Hedgehog signaling pathway that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF).
Who invested in Endeavor BioMedicines
17 investors across 3 rounds
See all investors in Endeavor BioMedicines
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Endeavor BioMedicines
Who invested in Endeavor BioMedicines?
Endeavor BioMedicines has 17 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Endeavor BioMedicines raised?
Endeavor BioMedicines has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Endeavor BioMedicines last raise money?
Endeavor BioMedicines's most recent round on record is a Series C, in Apr 2024.
What does Endeavor BioMedicines do?
Endeavor BioMedicines is a biotechnology company.
Where is Endeavor BioMedicines headquartered?
Endeavor BioMedicines is headquartered in Solana Beach, US.
Which VCs invest in companies like Endeavor BioMedicines?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Endeavor BioMedicines's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Endeavor BioMedicines? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.